Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone long-term extension in Friedreich's ataxia
NL-OMON32601Phase 3Active, not recruiting
- Sponsor
- Santhera Pharmaceuticals
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of idebenone in Friedreich ataxia (FA), sponsored by Santhera Pharmaceuticals. Primary endpoints: Safety and tolerability, Change in ICARS score and 1 more. Started Jun 2009; status: active, not recruiting.
02
Drugs
idebenone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NL-OMON32601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32601.